{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:14:10Z","timestamp":1782231250724,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"University of Louisville office of Executive Vice-President for Research and Innovation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00408-024-00673-7","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T14:02:45Z","timestamp":1708437765000},"page":"139-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Identification of Idiopathic Pulmonary Fibrosis and Prediction of Disease Severity via Machine Learning Analysis of Comprehensive Metabolic Panel and Complete Blood Count Data"],"prefix":"10.1007","volume":"202","author":[{"given":"Alex N.","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann B.","family":"Frieboes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"673_CR1","unstructured":"U.S. National Library of Medicine, N.I.H. Idiopathic pulmonary fibrosis. https:\/\/ghr.nlm.nih.gov\/condition\/idiopathic-pulmonary-fibrosis. Accessed 30 Aug 2019"},{"issue":"6","key":"673_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G et al (2011) An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788\u2013824","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"673_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1164\/rccm.201306-1141WS","volume":"189","author":"TS Blackwell","year":"2014","unstructured":"Blackwell TS et al (2014) Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med 189(2):214\u2013222","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"673_CR4","first-page":"797","volume":"379","author":"DJ Lederer","year":"2018","unstructured":"Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. N Engl J Med 379(8):797\u2013798","journal-title":"N Engl J Med"},{"key":"673_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jcm10122663","volume":"10","author":"JH Chung","year":"2021","unstructured":"Chung JH et al (2021) Differentiation of idiopathic pulmonary fibrosis from connective tissue disease-related interstitial lung disease using quantitative imaging. J Clin Med 10:12","journal-title":"J Clin Med"},{"issue":"7","key":"673_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/17476348.2017.1335600","volume":"11","author":"A Suzuki","year":"2017","unstructured":"Suzuki A, Kondoh Y, Fischer A (2017) Recent advances in connective tissue disease related interstitial lung disease. Expert Rev Respir Med 11(7):591\u2013603","journal-title":"Expert Rev Respir Med"},{"key":"673_CR7","first-page":"1","volume":"10","author":"GL Erre","year":"2021","unstructured":"Erre GL et al (2021) Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs Context 10:1","journal-title":"Drugs Context"},{"key":"673_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-019-0971-8","volume":"20","author":"C Hayton","year":"2019","unstructured":"Hayton C et al (2019) Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. Respir Res 20:1","journal-title":"Respir Res"},{"key":"673_CR9","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2019\/e225","volume":"74","author":"B Hochhegger","year":"2019","unstructured":"Hochhegger B et al (2019) Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics. Clinics (Sao Paulo) 74:e225","journal-title":"Clinics (Sao Paulo)"},{"issue":"5","key":"673_CR10","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198(5):e44\u2013e68","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"673_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00408-017-9993-5","volume":"195","author":"J Guiot","year":"2017","unstructured":"Guiot J et al (2017) Blood biomarkers in idiopathic pulmonary fibrosis. Lung 195(3):273\u2013280","journal-title":"Lung"},{"key":"673_CR12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/medicina55010005","volume":"55","author":"Y Hachisu","year":"2019","unstructured":"Hachisu Y et al (2019) Possible serological markers to predict mortality in acute exacerbation of idiopathic pulmonary fibrosis. Medicina (Kaunas) 55:5","journal-title":"Medicina (Kaunas)"},{"issue":"12","key":"673_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","volume":"5","author":"TM Maher","year":"2017","unstructured":"Maher TM et al (2017) An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med 5(12):946\u2013955","journal-title":"Lancet Respir Med"},{"key":"673_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745233","volume":"12","author":"T Zhang","year":"2021","unstructured":"Zhang T et al (2021) KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis. Front Immunol 12:745233","journal-title":"Front Immunol"},{"issue":"5","key":"673_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00408-020-00386-7","volume":"198","author":"A Zinellu","year":"2020","unstructured":"Zinellu A et al (2020) Blood cell count derived inflammation indexes in patients with idiopathic pulmonary fibrosis. Lung 198(5):821\u2013827","journal-title":"Lung"},{"issue":"1","key":"673_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000504763","volume":"99","author":"WA Wuyts","year":"2020","unstructured":"Wuyts WA et al (2020) Idiopathic pulmonary fibrosis: best practice in monitoring and managing a relentless fibrotic disease. Respiration 99(1):73\u201382","journal-title":"Respiration"},{"issue":"2","key":"673_CR17","first-page":"51","volume":"6","author":"E Fern\u00e1ndez Fabrellas","year":"2018","unstructured":"Fern\u00e1ndez Fabrellas E et al (2018) Prognosis and follow-up of idiopathic pulmonary fibrosis. Med Sci 6(2):51","journal-title":"Med Sci"},{"issue":"1","key":"673_CR18","first-page":"70","volume":"24","author":"S Stephan","year":"2007","unstructured":"Stephan S et al (2007) Oxygen desaturation during a 4-minute step test: predicting survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 24(1):70\u201376","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"673_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(4):431\u2013440","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"673_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1479972315603714","volume":"13","author":"O Nishiyama","year":"2016","unstructured":"Nishiyama O et al (2016) Prognostic value of forced expiratory volume in 1 second\/forced vital capacity in idiopathic pulmonary fibrosis. Chron Respir Dis 13(1):40\u201347","journal-title":"Chron Respir Dis"},{"issue":"6","key":"673_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","volume":"194","author":"B Ley","year":"2016","unstructured":"Ley B et al (2016) Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 194(6):711\u2013718","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"673_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD et al (2013) An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733\u2013748","journal-title":"Am J Respir Crit Care Med"},{"key":"673_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pst.185","volume":"4","author":"SA Julious","year":"2005","unstructured":"Julious SA (2005) Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat 4:287\u2013291","journal-title":"Pharm Stat"},{"issue":"5","key":"673_CR24","first-page":"440","volume":"56","author":"L-P Nguyen","year":"2016","unstructured":"Nguyen L-P, Harper RW, Louie S (2016) Using and interpreting carbon monoxide diffusing capacity (DLco) correctly. Consultant 56(5):440\u2013445","journal-title":"Consultant"},{"key":"673_CR25","doi-asserted-by":"crossref","unstructured":"Dempsey TM, Scanlon PD (2018) Pulmonary function tests for the generalist: a brief review. In: Mayo Clinic proceedings. Elsevier, Amsterdam","DOI":"10.1016\/j.mayocp.2018.04.009"},{"issue":"5","key":"673_CR26","first-page":"359","volume":"89","author":"JD Johnson","year":"2014","unstructured":"Johnson JD, Theurer WM (2014) A stepwise approach to the interpretation of pulmonary function tests. Am Fam Phys 89(5):359\u2013366","journal-title":"Am Fam Phys"},{"issue":"9","key":"673_CR27","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205(9):e18\u2013e47","journal-title":"Am J Respir Crit Care Med"},{"key":"673_CR28","unstructured":"van Buuren S et al (2015) Package \u2018mice\u2019. Computer software"},{"issue":"8","key":"673_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002847","volume":"3","author":"AK Waljee","year":"2013","unstructured":"Waljee AK et al (2013) Comparison of imputation methods for missing laboratory data in medicine. BMJ Open 3(8):e002847","journal-title":"BMJ Open"},{"issue":"10","key":"673_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/08839514.2019.1637138","volume":"33","author":"A Jadhav","year":"2019","unstructured":"Jadhav A, Pramod D, Ramanathan K (2019) Comparison of performance of data imputation methods for numeric dataset. Appl Artif Intell 33(10):913\u2013933","journal-title":"Appl Artif Intell"},{"issue":"1","key":"673_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, B\u00fchlmann P (2012) MissForest\u2014non-parametric missing value imputation for mixed-type data. Bioinformatics 28(1):112\u2013118","journal-title":"Bioinformatics"},{"key":"673_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","volume":"13","author":"GS Collins","year":"2015","unstructured":"Collins GS et al (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med 13:1","journal-title":"BMC Med"},{"issue":"8","key":"673_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11306-022-01918-3","volume":"18","author":"HA Miller","year":"2022","unstructured":"Miller HA, van Berkel VH, Frieboes HB (2022) Lung cancer survival prediction and biomarker identification with an ensemble machine learning analysis of tumor core biopsy metabolomic data. Metabolomics 18(8):1\u201312","journal-title":"Metabolomics"},{"key":"673_CR34","unstructured":"Grandini M, Bagli E, Visani G (2020) Metrics for multi-class classification: an overview. arXiv preprint arXiv:2008.05756"},{"key":"673_CR35","doi-asserted-by":"crossref","unstructured":"Fatourechi M et al (2008) Comparison of evaluation metrics in classification applications with imbalanced datasets. In: 2008 seventh international conference on machine learning and applications, 2008. IEEE","DOI":"10.1109\/ICMLA.2008.34"},{"issue":"2","key":"673_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1164\/ajrccm.164.2.2105010a","volume":"164","author":"AL Katzenstein","year":"2001","unstructured":"Katzenstein AL, Myers JL (2001) Idiopathic pulmonary fibrosis: to biopsy or not to biopsy. Am J Respir Crit Care Med 164(2):185\u2013186","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"673_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1164\/ajrccm.164.2.2101090","volume":"164","author":"GW Hunninghake","year":"2001","unstructured":"Hunninghake GW et al (2001) Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164(2):193\u2013196","journal-title":"Am J Respir Crit Care Med"},{"key":"673_CR38","first-page":"1","volume":"1","author":"SB Montesi","year":"2020","unstructured":"Montesi SB et al (2020) Update in interstitial lung disease 2019. Am J Respir Crit Care Med 1:1","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"673_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.trsl.2012.01.012","volume":"159","author":"R Vij","year":"2012","unstructured":"Vij R, Noth I (2012) Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 159(4):218\u2013227","journal-title":"Transl Res"},{"issue":"12","key":"673_CR40","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.3390\/ijms22126255","volume":"22","author":"A Stainer","year":"2021","unstructured":"Stainer A et al (2021) Molecular biomarkers in idiopathic pulmonary fibrosis: state of the art and future directions. Int J Mol Sci 22(12):6255","journal-title":"Int J Mol Sci"},{"issue":"10","key":"673_CR41","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3390\/jcm8101698","volume":"8","author":"E Krauss","year":"2019","unstructured":"Krauss E et al (2019) Exploring the ability of electronic nose technology to recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): a pilot study from the European IPF Registry (eurIPFreg) and Biobank. J Clin Med 8(10):1698","journal-title":"J Clin Med"},{"issue":"4","key":"673_CR42","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7163\/ab8c2e","volume":"14","author":"S Dragonieri","year":"2020","unstructured":"Dragonieri S et al (2020) Exhaled volatile organic compounds analysis by e-nose can detect idiopathic pulmonary fibrosis. J Breath Res 14(4):047101","journal-title":"J Breath Res"},{"issue":"1","key":"673_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12931-019-0971-8","volume":"20","author":"C Hayton","year":"2019","unstructured":"Hayton C et al (2019) Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. Respir Res 20(1):7","journal-title":"Respir Res"},{"issue":"2","key":"673_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00408-017-9979-3","volume":"195","author":"YI Yamada","year":"2017","unstructured":"Yamada YI et al (2017) Volatile organic compounds in exhaled breath of idiopathic pulmonary fibrosis for discrimination from healthy subjects. Lung 195(2):247\u2013254","journal-title":"Lung"},{"issue":"1","key":"673_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12931-021-01923-5","volume":"23","author":"L Plantier","year":"2022","unstructured":"Plantier L et al (2022) The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study. Respir Res 23(1):12","journal-title":"Respir Res"},{"key":"673_CR46","doi-asserted-by":"crossref","unstructured":"Taylor MJ et al (2024) Disease diagnosis and severity classification in pulmonary fibrosis using carbonyl volatile organic compounds in exhaled breath. Respir Med (in press)","DOI":"10.1016\/j.rmed.2024.107534"},{"key":"673_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107798","volume":"222","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P et al (2021) Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther 222:107798","journal-title":"Pharmacol Ther"},{"issue":"14","key":"673_CR48","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.3390\/jcm10143167","volume":"10","author":"E Cabrera Cesar","year":"2021","unstructured":"Cabrera Cesar E et al (2021) Serum biomarkers in differential diagnosis of idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease. J Clin Med 10(14):3167","journal-title":"J Clin Med"},{"issue":"5","key":"673_CR49","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1378\/chest.116.5.1168","volume":"116","author":"G Raghu","year":"1999","unstructured":"Raghu G et al (1999) The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 116(5):1168\u20131174","journal-title":"Chest"},{"issue":"10","key":"673_CR50","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/medicina57101121","volume":"57","author":"T Kishaba","year":"2021","unstructured":"Kishaba T et al (2021) Radiological and physiological predictors of IPF mortality. Medicina 57(10):1121","journal-title":"Medicina"},{"issue":"4","key":"673_CR51","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1183\/09031936.00155108","volume":"35","author":"C Zappala","year":"2010","unstructured":"Zappala C et al (2010) Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 35(4):830\u2013836","journal-title":"Eur Respir J"},{"issue":"1","key":"673_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1172\/JCI110242","volume":"68","author":"GW Hunninghake","year":"1981","unstructured":"Hunninghake GW et al (1981) Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 68(1):259\u2013269","journal-title":"J Clin Invest"},{"issue":"1","key":"673_CR53","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12890-021-01598-0","volume":"21","author":"U Schmid","year":"2021","unstructured":"Schmid U et al (2021) Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. BMC Pulm Med 21(1):244","journal-title":"BMC Pulm Med"},{"issue":"2","key":"673_CR54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s41030-017-0049-z","volume":"3","author":"L Lancaster","year":"2017","unstructured":"Lancaster L et al (2017) Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: experience from 92 sites in an open-label US expanded access program. Pulm Ther 3(2):317\u2013325","journal-title":"Pulm Ther"},{"issue":"1","key":"673_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.resinv.2016.08.003","volume":"55","author":"S Ikeda","year":"2017","unstructured":"Ikeda S et al (2017) Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: a single-center experience. Respir Investig 55(1):51\u201354","journal-title":"Respir Investig"},{"issue":"2","key":"673_CR56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jpen.1451","volume":"43","author":"PB Soeters","year":"2019","unstructured":"Soeters PB, Wolfe RR, Shenkin A (2019) Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr 43(2):181\u2013193","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"3","key":"673_CR57","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1042\/bj2650621","volume":"265","author":"PC Heinrich","year":"1990","unstructured":"Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265(3):621\u2013636","journal-title":"Biochem J"},{"issue":"4","key":"673_CR58","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1378\/chest.08-0754","volume":"135","author":"DA Zisman","year":"2009","unstructured":"Zisman DA et al (2009) Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia. Chest 135(4):929\u2013935","journal-title":"Chest"},{"key":"673_CR59","doi-asserted-by":"crossref","unstructured":"American Thoracic S, European Respiratory S (2002) American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2):277\u2013304.","DOI":"10.1164\/ajrccm.165.2.ats01"},{"issue":"6","key":"673_CR60","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/MAJ.0b013e31821a9d8e","volume":"341","author":"DF Zoz","year":"2011","unstructured":"Zoz DF, Lawson WE, Blackwell TS (2011) Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction. Am J Med Sci 341(6):435\u2013438","journal-title":"Am J Med Sci"},{"issue":"1","key":"673_CR61","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12890-023-02562-w","volume":"23","author":"YH Chen","year":"2023","unstructured":"Chen YH et al (2023) Clinical outcomes and risk factors of progressive pulmonary fibrosis in primary Sjogren\u2019s syndrome-associated interstitial lung disease. BMC Pulm Med 23(1):268","journal-title":"BMC Pulm Med"},{"key":"673_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106068","volume":"170","author":"SD Nathan","year":"2020","unstructured":"Nathan SD et al (2020) The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. Respir Med 170:106068","journal-title":"Respir Med"},{"issue":"1","key":"673_CR63","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12890-019-0933-4","volume":"19","author":"L Xu","year":"2019","unstructured":"Xu L et al (2019) High hemoglobin is associated with increased in-hospital death in patients with chronic obstructive pulmonary disease and chronic kidney disease: a retrospective multicenter population-based study. BMC Pulm Med 19(1):174","journal-title":"BMC Pulm Med"},{"key":"673_CR64","first-page":"8","volume":"56","author":"VM Ruta","year":"2020","unstructured":"Ruta VM et al (2020) Neutrophil-to-lymphocyte ratio and systemic immune-inflammation index-biomarkers in interstitial lung disease. Medicina (Kaunas) 56:8","journal-title":"Medicina (Kaunas)"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00673-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-024-00673-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00673-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T09:04:42Z","timestamp":1712912682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-024-00673-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1007\/s00408-024-00673-7","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}